Nuvalent, Inc. Share Price & Technical Analysis
NUVL · $102.1 (+0.87%)
Healthcare / Biotechnology
$102.1
+0.87%
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine ki…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, 4% avg return in past 3 year May month.
3% return in 2026, 51% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | -1% | 2% | -3% | 2% | – | – | – | – | – | – | – | 3% |
| 25 | 8% | -11% | -5% | 8% | -3% | 2% | 2% | -2% | 13% | 15% | 11% | -7% | 33% |
| 24 | 4% | 12% | -11% | -11% | -5% | 16% | 6% | 7% | 23% | -13% | 9% | -20% | 17% |
| 23 | 0% | 0% | -14% | 36% | 19% | 0% | 19% | -8% | 0% | 13% | 26% | 13% | 104% |
| 22 | -27% | 10% | -5% | -26% | -14% | 53% | 10% | 16% | 15% | 82% | -10% | -9% | 94% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$8.15B
P/E ratio
—
52W high
$113.0
52W low
$70.25
Volume
5,26,956
Beta
1.15
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Nuvalent, Inc. share price today?
- Nuvalent, Inc. (NUVL) last traded around $102.1 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NUVL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NUVL. Download the app for real-time alerts.
- How can I analyze Nuvalent, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.